279 related articles for article (PubMed ID: 16813563)
1. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Jun; 396(3):537-45. PubMed ID: 16492138
[TBL] [Abstract][Full Text] [Related]
3. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2004 Sep; 43(38):12081-9. PubMed ID: 15379547
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
5. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
[TBL] [Abstract][Full Text] [Related]
6. Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Jun; 278(23):20449-52. PubMed ID: 12711602
[TBL] [Abstract][Full Text] [Related]
7. Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Dec; 278(50):50136-41. PubMed ID: 14522974
[TBL] [Abstract][Full Text] [Related]
8. Human P-glycoprotein is active when the two halves are clamped together in the closed conformation.
Loo TW; Bartlett MC; Clarke DM
Biochem Biophys Res Commun; 2010 May; 395(3):436-40. PubMed ID: 20394729
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Oct; 278(41):39706-10. PubMed ID: 12909621
[TBL] [Abstract][Full Text] [Related]
10. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
Loo TW; Clarke DM
Biochemistry; 1999 Apr; 38(16):5124-9. PubMed ID: 10213617
[TBL] [Abstract][Full Text] [Related]
11. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2005 Apr; 329(2):419-22. PubMed ID: 15737603
[TBL] [Abstract][Full Text] [Related]
12. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
13. Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site.
Loo TW; Clarke DM
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3511-6. PubMed ID: 11891276
[TBL] [Abstract][Full Text] [Related]
14. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
Rao US
Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
[TBL] [Abstract][Full Text] [Related]
15. Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein.
Storm J; O'Mara ML; Crowley EH; Peall J; Tieleman DP; Kerr ID; Callaghan R
Biochemistry; 2007 Sep; 46(35):9899-910. PubMed ID: 17696319
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains.
Kwan T; Gros P
Biochemistry; 1998 Mar; 37(10):3337-50. PubMed ID: 9521654
[TBL] [Abstract][Full Text] [Related]
17. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment.
Rothnie A; Storm J; McMahon R; Taylor A; Kerr ID; Callaghan R
FEBS Lett; 2005 Jul; 579(18):3984-90. PubMed ID: 16004994
[TBL] [Abstract][Full Text] [Related]
18. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Feb; 279(9):7692-7. PubMed ID: 14670948
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
[TBL] [Abstract][Full Text] [Related]
20. Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micelles.
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2017 Jul; 488(4):573-577. PubMed ID: 28533092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
